Posted by Michael Wonder on 29 May 2017
UK’s NICE recommends Novartis’ Afinitor to treat neuroendocrine tumours
29 May 2017 - The UK’s NICE has recommended Novartis’ Afinitor (everolimus) to treat unresectable or metastatic neuroendocrine tumours in patients with progressive disease.
The recommendation covers the drug as therapy for neuroendocrine tumours (NETs) that are well- or moderately-differentiated, unresectable or metastatic, and of pancreatic origin in patients with progressive disease.
Afinitor has also been recommended by the health body to be used as therapy for well-differentiated non-functional unresectable or metastatic NETs of gastrointestinal or lung origin in adults with progressive disease.
